Format

Send to

Choose Destination
Curr Opin Cardiol. 2020 Mar;35(2):178-186. doi: 10.1097/HCO.0000000000000704.

Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.

Author information

1
Department of Anesthesia.
2
Department of Physiology.
3
Division of Endocrinology and Metabolism, The Ottawa Hospital, University of Ottawa, Ottawa.
4
Division of Cardiology.
5
Department of Medicine.
6
Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre.
7
Department of Internal Medicine, Humber River Hospital, Toronto.
8
Division of Endocrinology and Metabolism, Queen's University, Kingston.
9
Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital.
10
Department of Surgery.
11
Department of Pharmacology and Toxicology, University of Toronto, Toronto.
12
LMC Diabetes & Endocrinology, Concord, Ontario, Canada.

Abstract

PURPOSE OF REVIEW:

The aim of this article is to provide practical recommendations on safe initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors to in-patients as well as management of those who are already on SGLT2 inhibitors.

RECENT FINDINGS:

Robust data from stable outpatient cohorts indicate that the SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, lower rates of hospitalization for heart failure, and a reduction in major kidney outcomes There is however a lack of information on how to initiate and manage SGLT2 inhibitors in an acute in-patient setting.

SUMMARY:

SGLT2 inhibitors may be cautiously appropriate for in-patients if all the criteria for safe use are met but good clinical judgment must prevail. Temporary withholding of SGLT2 inhibitors is appropriate in hospitalized patients during a period of stress and/or insulinopenia.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center